Trial intelligence / Profile preview

Dasatinib versus imatinib in chronic-phase chronic myeloid leukemia with suboptimal 3-month response to first-line imatinib

2011-006181-41Phase 2Completed

Sponsor

Bristol Myers Squibb

Start

Nov 2012

Modality

Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules

Countries

1